Literature DB >> 16355921

Breast cancer biomarkers.

Jeffrey S Ross1, W Fraser Symmans, Lajos Pusztai, Gabriel N Hortobagyi.   

Abstract

Substantial progress has been made over the past three decades in our understanding of the epidemiology, clinical course and basic biology of breast cancer. This chapter considers the existing ancillary tests and emerging molecular markers in breast cancer prognosis assessment and the prediction of response of breast cancer to treatment of the disease.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16355921     DOI： 10.1016/s0065-2423(05)40003-7

Source DB:  PubMed          Journal:  Adv Clin Chem        ISSN： 0065-2423            Impact factor:   5.394


  9 in total

1.  Breast imaging: A survey.

Authors:  Subbhuraam Vinitha Sree; Eddie Yin-Kwee Ng; Rajendra U Acharya; Oliver Faust
Journal:  World J Clin Oncol       Date:  2011-04-10

Review 2.  Breast and ovarian cancers: a survey and possible roles for the cell surface heparan sulfate proteoglycans.

Authors:  Atsuko Yoneda; Maria E Lendorf; John R Couchman; Hinke A B Multhaupt
Journal:  J Histochem Cytochem       Date:  2012-01       Impact factor: 2.479

3.  Syndecan-1 and syndecan-4 are independent indicators in breast carcinoma.

Authors:  Maria E Lendorf; Tina Manon-Jensen; Pauliina Kronqvist; Hinke A B Multhaupt; John R Couchman
Journal:  J Histochem Cytochem       Date:  2011-03-23       Impact factor: 2.479

4.  Optimal tumor sampling for immunostaining of biomarkers in breast carcinoma.

Authors:  Juliana Tolles; Yalai Bai; Maria Baquero; Lyndsay N Harris; David L Rimm; Annette M Molinaro
Journal:  Breast Cancer Res       Date:  2011-05-18       Impact factor: 6.466

Review 5.  Prediction of individual response to anticancer therapy: historical and future perspectives.

Authors:  Florian T Unger; Irene Witte; Kerstin A David
Journal:  Cell Mol Life Sci       Date:  2014-11-12       Impact factor: 9.261

6.  CD133 is a useful surrogate marker for predicting chemosensitivity to neoadjuvant chemotherapy in breast cancer.

Authors:  Naoki Aomatsu; Masakazu Yashiro; Shinichiro Kashiwagi; Tsutomu Takashima; Tetsuro Ishikawa; Masahiko Ohsawa; Kenichi Wakasa; Kosei Hirakawa
Journal:  PLoS One       Date:  2012-09-25       Impact factor: 3.240

7.  Evaluation of biological pathways involved in chemotherapy response in breast cancer.

Authors:  Attila Tordai; Jing Wang; Fabrice Andre; Cornelia Liedtke; Kai Yan; Christos Sotiriou; Gabriel N Hortobagyi; W Fraser Symmans; Lajos Pusztai
Journal:  Breast Cancer Res       Date:  2008-04-29       Impact factor: 6.466

8.  Carbonic anhydrase 9 is associated with chemosensitivity and prognosis in breast cancer patients treated with taxane and anthracycline.

Authors:  Naoki Aomatsu; Masakazu Yashiro; Shinichiro Kashiwagi; Hidemi Kawajiri; Tsutomu Takashima; Masahiko Ohsawa; Kenichi Wakasa; Kosei Hirakawa
Journal:  BMC Cancer       Date:  2014-06-04       Impact factor: 4.430

Review 9.  Tamoxifen Resistance: Emerging Molecular Targets.

Authors:  Milena Rondón-Lagos; Victoria E Villegas; Nelson Rangel; Magda Carolina Sánchez; Peter G Zaphiropoulos
Journal:  Int J Mol Sci       Date:  2016-08-19       Impact factor: 5.923
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.